Medical and nutritional therapy for Crohn's disease

Current Opinion in Gastroenterology

Volumn 12, Issue 4, 1996, Pages 356-362

  Hilsden, Robert J ^a   Sutherland, Lloyd R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; FISH OIL; MERCAPTOPURINE; MESALAZINE; TUMOR NECROSIS FACTOR ANTIBODY;

CROHN DISEASE; DRUG BIOAVAILABILITY; HUMAN; NUTRITION; RELAPSE; REMISSION; REVIEW;

EID: 0029813676     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199607000-00008     Document Type: Review

References (60)

1. Wright JP, Jewell DP, Modigliani R, Malchow H: A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease. Inflamm Bowel Dis 1996, 1:241-246.
2. Singleton JW, Hanauer S, Robinson M: Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci 1995, 40:931-935.
3. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, d'Albasio G, De Simone G, Martini N: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994, 89:692-698.
4. Steinhart AH, Hemphill D, Greenberg GR: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994, 89:2116-2124.
5. McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, Blair JE, Cangemi JR, Cohen Z, Cullen JB: Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995, 109:404-413. Mesalamine started within 8 days of resection decreased the risk of recurrence, but the greatest benefit was seen in patients with large bowel disease.
6. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, D'Arienzo A, d'Albasio G, Pennestri D: Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995, 108:345-349. Mesalamine decreased the rate of severe endoscopic recurrence following intestinal resection.
7. Arber N, Odes HS, Fireman Z, Lavie A, Broide E, Bujanover Y, Becker S, Pomerantz I, Moshkowitz M, Patz J: A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995, 20:203-206. Low-dose mesalamine (1 g/d) prolonged remission in patients with small bowel disease.
8. Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Dallaire C, Poleski M, Harvey W, Lariviere L: 5-Aminosalicylic acid In the maintenance of remission of Crohn's disease [abstract]. Gastroenterology 1995, 108:924. Large multicenter study failed to show a benefit for Pentasa in maintaining remission, although subgroup analysis suggested a benefit in women.
9. Thomson ABR, Wright JP, Vatn M, Bailey RJ, Rachmilewitz D, Adler M: Mesalazine 1.5 g BID daily versus placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995, 9:673-683. Mesalamine, 1.5 g twice daily, did not prolong remission compared with placebo in patients with medically or surgically induced remission.
10. Modigliani R, Colombel J, Dupas JL, Dapoigny M, Bouhnik Y, Veyrac M, Cadiot G, Duclos B, Soulé JC, Gendre JP, et al.: Mesalamine in Crohn's disease patients with prednisolone-induced remission: effect on steroid weaning and remission maintenance in the year after weaning. A placebo-controlled, multicentre double-blind trial [abstract]. Gastroenterology 1995, 108:878.
11. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994, 331:842-845.
12. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson L-G, Persson T: Oral budesonide for active Crohn's disease. N Engl J Med 1994, 331-836-841.
13. Gross V, Andus T, Caesar I, Manns M, Lochs H, Genser D, May B, Schultz HJ, Bär U, Überschaer B, et al.: Oral pH-modified release budesonide vs 6-methylprednisolone in active Crohn's disease [abstract]. Gastroenterology 1995, 108:828.
14. Campieri M, Ferguson A, Doe W: Oral budesonide competes favourably with prednisolone in active Crohn's disease [abstract]. Gastroenterology 1995, 108:790.
15. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson L, Persson T: Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996, 110:45-51. Budesonide at dosages of 3 or 6 mg/d did not prolong remission compared with placebo.
16. Gross V, Andus T, Ecker KW, Raedler A, Loeskchke K, Weber A, Gierend M, Ewe K, Schölmerich J: Oral pH-modified release budesonide for maintenance of steroid induced remission in Crohn's disease: an interim analysis. Gastroenterology 1995, 108:A828.
17. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678. In subjects treated with a combination of azathioprine and tapered-dose prednisone, the disease remained in remission longer than in subjects treated with prednisone alone.
18. D'Haens G, Peeters M, Geboes K, Rutgeerts P: Azathioprine induces mucosal healing in severe recurrent Crohn's ileitis after surgery [abstract]. Gastroenterology 1995, 108:809.
19. Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995, 122:132-142. A meta-analysis of published trials of 6-mercaptopurine and azathioprine confirming that the drugs are effective for inducing and maintaining remission.
20. Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ: An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995, 109:1808-1817. Uncontrolled study of an intravenous loading dose of azathioprine showing promising results, with rapid clinical improvement and closure of fistulas.
21. Stange EF, Modigiani R, Pena AS, Wood AJ, Feutren G, Smith PR: European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology 1995, 109:774-782. This well-designed study failed to show any improvement in induction or maintenance of remission with the use of low-dose oral cyclosporine compared with placebo.
22. Sanborn WJ: Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology 1995, 109:1001-1003.
23. Lichtiger S: To use or not to use cyclosporine-A: that is the question. Inflamm Bowel Dis 1995, 1:331-334.
24. Feagan BG: Cyclosporine has no proven role as a therapy for Crohn's disease, Inflamm Bowel Dis 1995, 1:335-339.
25. Banks PA, Present DH: Is there any value in using cyclosporine in the treatment of Crohn's disease: to use or not to use? Inflamm Bowel Dis 1995, 1:340
26. Santos JV, Baudet JA, Casellas FJ, Guarner LA, Vilaseca JM, Malagelada JR: Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease: short- and long-term results. J Clin Gastroenterol 1995, 20:207-210.
27. Van Kruiningen HJ: On the use of antibiotics in Crohn's disease. J Clin Gastroenterol 1996, 20:310-316.
28. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995, 108:1617-1621. A 3-month course of metronidazole reduced the risk of recurrence at 12 months but not at 24 months following ileal resection.
29. Present DH: The prevention of Crohn's disease after surgery: metronidazole is a small but continuous medical advancement. Gastroenterology 1995, 108:1935-1938.
30. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C: Metronidazole plus ciprofloxacin for the treatment of active Crohn's disease: a randomized controlled trial. Am J Gastroenterol 1996, 91:328-332.
31. Turunen U, Färkkilä M, Hakala K, Vuoristo M, Rahm V, Seppälä K, Valtonen V, Miettinen TA: Ciprofloxacin treatment combined with conventional therapy in Crohn's disease: a prospective, double-blind, placebo controlled study [abstract]. Gut 1995, 37:193.
32. Graham DY, Al-Assi MT, Robinson M: Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection [abstract]. Gastroenterology 1995, 108:826. Treatment for M. paratuberculosis infection with clarithromycin prolonged remission, suggesting that confirmation of these preliminary findings should be sought in larger randomized trials. Whether subjects were actually infected with M. paratuberculosis is unknown; therefore, the exact mechanism for the prolonged remission is unclear.
33. Braegger CP, Nichols S, Murch SH, Stephens S, MacDonald TT: Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 339:89-91.
34. Lukacs NW, Chensue SW, Strieter R, Warmington K, Kunkel SL: Inflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1. J Immunol 1994, 152:5883-5889.
35. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135. Small uncontrolled study of anti-TNF chimeric monoclonal antibody (cA2) shows promising results for this novel therapy.
36. Belluzzi A, Brignola C, Campieri M, Pera A, Camporesi E, Boschi S, Rizzello F, Belloli C, De Simone G, Astegiano M, et al.: New fish oil derivative for preventing clinical relapses in Crohn's disease: a double blind placebo controlled randomized trial. Gastroenterology 1995, 108:A781. Preliminary findings from a double-blind, placebo-controlled study show that a well-tolerated preparation of fish oil reduced the risk of relapse compared with placebo.
37. Gasché C, Reinisch W, Vogelsang H, Potzi R, Markis E, Micksche M, Wirth HP, Gangl A, Lochs H: Prospective evaluation of interferon-a in treatment of Crohn's disease. Dig Dis Sci 1995, 40:800-804.
38. Davidsen B, Munkholm P, Schlichting P, Nielsen OH, Krarup H, Bonnevie-Nielsen V: Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. Aliment Pharmacol Ther 1995, 9:75-79.
39. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR: Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995, 108:1056-1067. A meta-analysis of published studies indicating that corticosteroids are more effective than enterai nutrition and that sufficient evidence is lacking to support an advantage for elemental feeding compared with polymeric feeding.
40. Fernández-Bañares F, Cabré E, Esteve-Comas M, Gassull MA: How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of randomized clinical trials. JPEN J Parenter Enteral Nutr 1995, 19:356-364.
41. Wu S, Craig RM: Intense nutritional support in inflammatory bowel disease. Dig Dis Sci 1995, 40:843-852.
42. Fleming CR: Nutrition in patients with Crohn's disease: another piece of the puzzle [editorial]. JPEN J Parenter Enteral Nutr 1995, 19:93-94.
43. Herzog D, Bouthillier L, Parent P, Lepage G, Roy C, Seidman E: Essential fatty acid sufficient elemental diet therapy in pediatric Crohn's disease: effect on nutritional and inflammatory parameters. Gastroenterology 1995, 108:A833.
44. Mansfield JC, Giaffer MH, Holdsworth CD: Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease. Gut 1995, 36:60-66.
45. Messing B, Lémann M, Landais P, Gouttebel M, Gérard-Boncompain M, Saudin F, Vangossum A, Beau P, Guédon C, Barnoud D, et al.: Prognosis of patients with nonmalignant chronic intestinal failure receiving long-term home parenteral nutrition. Gastroenterology 1995, 108:1005-1010.
46. Howard L, Ament M, Fleming CR, Shike M, Steiger E: Current use and clinical outcome of home parenteral and enterai nutrition therapies in the United States. Gastroenterology 1995, 109.355-365.
47. Rhodes J, Bainton D, Beck P, Campbell H: Controlled trial of azathioprine in Crohn's disease. Lancet 1971, 2:1273-1276.
48. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H: Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974, 66:916-922.
49. Summers RW, Switz JT, Sessions JT, Brektel JM, Best WR, Singleton JW: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979, 77:847-869.
50. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Meyer zum Buschenfelde KH: Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993, 105:367-372.
51. Present DH, Korelitz BI, Glass JL, Sachar DB, Pasternack BS: Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized, double-bind study. N Engl J Med 1980, 302:981-987.
52. Willioughby JM, Beckett J, Kumar PJ, Dawson AM: Controlled trial of azathioprine in Crohn's disease. Lancet 1971, 2:944-947.
53. Lochs H, Steinhardt HJ, Klaus-Wentz B, Zeitz M, Vogelsang H, Sommer H, Fleig WE, Bauer P, Schirrmeister J, Malchow H: Comparison of enterai nutrition and drug treatment in active Crohn's disease: results of the European Cooperative Crohn's Disease Study IV. Gastroenterology 1991, 101:881-888.
54. Malchow H, Steinhardt HJ, Lorenz-Meyer H, Strohm WD, Rasmussen S, Sommer H, Jarnum S, Brandes JW, Leonhardt K, Ewe K, Jesdinsky H: Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease: European Cooperative Crohn's Disease Study III. Scand J Gastroenterol 1990, 25:235-244.
55. Gonzales-Huix F, De Leon R, Fernandez-Banares F, Esteve M, Cabre E, Acero D, Abad-Lacruz A, Figa M, Guilera M, Planas R: Polymeric enterai diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 1993, 34:778-782.
56. Gorard DA, Hunt JB, Payne-James JJ, Palmer KR, Rees RG, Clark ML, Farthing MJ, Misiewicz JJ, Silk DB: Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 1993, 34:1198-1202.
57. Lindor KD, Fleming CR, Burnes JU, Nelson JK, Ilstrup DM: A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease. Mayo Clin Proc 1992, 67:328-333.
58. O'Morain C, Segal AW, Levi AJ: Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. BMJ 1984, 288:1859-1862.
59. Seidman EG, Lohoues MJ, Turgeon J, Bouthillier L, Morin CL: Elemental diet versus prednisone as initial therapy in Crohn's disease: early and long-term results [abstract]. Gastroenterology 1991, 100:250.
60. Seidman EG, Griffiths AM, Jones A, Issenman R, The Canadian Paediatric Crohn's Disease Study Group: Semielemental diet versus prednisone in the treatment of active Crohn's disease in children and adolescents [abstract]. Gastroenterology 1993, 104:778.